Find Clinical Trial

A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.

← Back
Study Phase

Phase 3

Therapeutic Area


IndicationNon Infectious Uveitis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS078989
Protocol CodeCL3-78989-019
EudraCT Code2013-004973-29
NCT CodeNCT02375685

Documents and links

Results summary READ MORE
Scientific publication READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.